Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q3 2023 · 10-Q
Revenue$15.56M$15.56M−8.7% vs Q3 2022 Net Income$5.10B$5.10BN/M vs Q3 2022 EPS Diluted$6.03$6.03N/M vs Q3 2022 Operating Income$5,127,455,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$210,807,000N/M Margins · derivedOperating margin32948.6%+35165.8 pt vs Q3 2022
Net margin32747.6%+34812.0 pt vs Q3 2022
ended Dec 31, 2023 · filed Feb 13, 2024 · 44 d after period end